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MDM2 is a key regulator of the p53 tumor suppressor protein and is overexpressed in many human cancers. Two single nucle-
otide polymorphisms (SNPs) located in the MDM2 intronic promoter (P2) have been found to exert biological function. The G-
allele of SNP309T>G; rs2279744 increases MDM2 transcription and has been linked to increased cancer risk. In contrast, the
less frequent SNP285G>C; rs117039649, which is in complete linkage disequilibrium with SNP309 (generating a SNP285C/
309G variant haplotype), has been related to reduced MDM2 transcription and to reduced risk of breast, endometrial and ovar-
ian cancer. In this large population-based case–control study, we genotyped SNP309 and SNP285 in 10,830 individuals,
including cases with cancer of the breast (n51,717), colon (n51,532), lung (n51,331) and prostate (n52,501), as well as
3,749 non-cancer controls. We found a slightly reduced risk for lung cancer among individuals harboring the SNP309TG/GG
genotypes compared to the SNP309TT genotype (OR5 0.86; CI50.67–0.98), but this association was restricted to women
(OR50.77; CI50.63–0.95) and was not present among men (OR50.91; CI50.77–1.08). Consistent with previous findings,
we found a reduced risk for breast cancer among individuals carrying the SNP285GC/309GG genotype versus the SNP285GG/
309GG genotype (OR50.55; CI50.33–0.93). In conclusion, our data support the hypothesis that the effects of both SNP285
and SNP309 status are tissue dependent.
The protein product of the human homologue of Murine
Double Minute 2 (MDM2) gene is a key regulator of the p53
tumor suppressor protein. The negative regulation is primar-
ily executed through MDM2’s function as an ubiquitin E3
ligase,1,2 but MDM2 also inhibits the transcriptional activity
of p53 through direct binding.3,4 Recently, Gaijjer et al.5
reported the MDM2 protein to bind and stabilize p53 mRNA
in response to genotoxic stress, thereby adding further evi-
dence to this complex interaction. Since MDM2 harbors p53
responsive elements in its inducible intronic promoter P2, a
ﬁne tuned negative feedback loop mechanism is likely to be
present.6
Elevated MDM2 levels due to MDM2 gene ampliﬁcation
and/or protein overexpression has been observed in several
human cancers harboring wild-type p53,7,8 and has been sug-
gested to be an alternative mechanism for p53 inactivation in
tumorigenesis and tumor progression.9
A functional single nucleotide polymorphism (SNP)
located at position 309 downstream of exon 1 (SNP309
T>G; rs2279744) within the MDM2 intronic P2 promoter
has been shown to enhance binding of the Sp1 transcription
factor, resulting in elevated MDM2 expression levels.10 The
initial reports indicated the SNP309G variant to be associated
with increased cancer risk and early cancer development.10–12
Subsequently, epidemiological studies covering several cancer
forms and different ethnic groups have assessed the impact
of SNP309G on tumor risk and age at diagnosis.13–15 Taken
together, the data from these studies indicate that SNP309G
increases cancer risk among individuals of Asian ancestry,
while the results in Europeans have been inconsistent.13,14
Recently, we reported a second polymorphism in the pro-
moter P2 region of MDM2, (SNP285 G>C; rs117039649) sit-
uated 24 bps upstream of SNP309.16 The SNP285C variant
resides on the SNP309G allele, thus forming a distinct
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SNP285C/309G haplotype.16,17 The C-allele of SNP285 seems
to antagonize the effect of SNP309G by reducing the binding
afﬁnity of the Sp1 transcription factor to the MDM2 pro-
moter.16,18 Moreover, the SNP285C/309G haplotype has been
associated with a reduced risk for ovarian, breast and endome-
trial cancer16,19,20 but was found not to be associated with risk
for cancer of the prostate or lung.19,21 Finally, the SNP285C
has also been found to reduce the risk of BRCA1 related ovar-
ian cancer in individuals carrying the SNP309G allele.22
While the SNP285C/309G haplotype is observed in
approximately 11% of the SNP309G alleles across all Cauca-
sian populations, except for a low frequency in the Finnish
and the Saami populations (1.9% and 0.3%, respectively), it is
absent among individuals of Asian (Chinese, Mongolian and
Japanese) and African (Afro-Americans, Kenyans and Niger-
ians) heritage.16,23,24 Thus, the presence of the SNP285C
variant in Europeans could be an underlying reason for the
conﬂicting ﬁndings regarding SNP309G on cancer risk in
different ethnic groups.
Considering the fact that the SNP285C has been found to
reduce the risk of female cancers (ovarian, endometrial and
breast) but not cancer of the prostate,16,19,20 it is interesting
to note that the estrogen receptor (ESR1) has been reported
to act as a transcriptional activator in concert with Sp125,26
and in silico predictions have shown that the MDM2 P2 pro-
moter contains an estrogen receptor binding element (ERE)
overlapping the Sp1 binding site harboring SNP285.19 Taken
together, this may suggest that the SNP285C allele could
have a gender-speciﬁc cancer protective effect.
To assess potential effects of SNP309G and SNP285C on can-
cer risk at a broader scale, we here conducted a large scale screen-
ing of MDM2 SNP285 and SNP309 status in a population based
case–control study in Norway. Thus, we included a total of 7,081
cancer incident cases (breast, prostate, colon and lung), and
3,479 non-cancer controls. We conﬁrmed our previous ﬁndings
that SNP285C may act as a protective factor against cancer of the
breast but not against prostate cancer. Further, we found a mod-
erate positive association between SNP309TT status as well as
SNP285C and lung cancer risk in women, but found no effect of
these two SNP variants and lung cancer risk in men; neither did
we observe any association with colon cancer risk in either gen-
der. Our ﬁndings argue against a major effect of SNP309 status
on the risk for cancer of the breast, prostate, lung or colon. In
contrast, they indicate a possible tissue speciﬁc protective effect
of SNP285C on cancer risk.
Material and Methods
Study Population
All cases and control samples in this study were obtained
from the population-based Cohort of Norway (CONOR)
study.27 All incident cancers were identiﬁed by linking the
identity of individuals participating in the CONOR study to
the Norwegian Cancer Registry from entry until the end of
2010. Thus, we analyzed 1,717 incident cases of breast cancer,
1,532 colon cancers, 1,331 lung cancers and 2,501 prostate
cancers (for details, see Supporting Information Fig. 1). As a
reference group, a total of 3,749 healthy controls from the
same cohort (matched to the cases with respect to age (in
ﬁve years groups), area of residence and gender) were ana-
lyzed (Supporting Information Fig. 1).
Six hundred and ﬁve of the prostate cancer cases were
included in a previous study.19 In addition, 71 of the male
controls included in this study overlapped with the controls
used in our previous study,19 thus, our study represents an
extension of the previous analysis related to prostate cancer.
With respect to smoking status, information about smok-
ing (current, former, never) was available for 1,264 lung can-
cer cases and 3,429 controls.
All sample donors included in the study had provided
written informed consent to anonymous genetic testing for
scientiﬁc purposes, and the study was approved by the
Regional Committee for Ethics in Medical Research (REK
Midt-Norge).
MDM2 Promoter Screening
All samples were genotyped for MDM2 SNP285
(rs117039649) and SNP309 (rs2279744) using custom Light-
SNiP assays (TIB MOLBIOL Syntheselabor GmbH, Berlin,
Germany) on a LightCycler 480 II instrument (Roche, Basel,
Switzerland) as previously described in detail elsewhere.24
Statistical Analysis
Potential deviations from Hardy-Weinberg equilibrium were
assessed by calculating the expected genotype distribution
based on the observed allele frequencies and compared with
the observed genotype distribution using Chi-square tests.
Potential associations between MDM2 SNP309 and
SNP285 and risk for cancer of the breast, colon, lung and
prostate were estimated by calculating odds ratio (OR) with
95% conﬁdence intervals (CI). The analyses were stratiﬁed by
What’s new?
The protein MDM2 grabs on to the tumor suppressor p53, stopping its transcription activity. In this study, the authors investi-
gated two MDM2 polymorphisms. The first, SNP309G, has been linked to increased cancer risk; the more recently identified
SNP285C may modulate the effects SNP309G. After screening 7,000 cases and half as many controls, the authors found a tis-
sue-specific effect. They report that SNP285C accompanies reduced breast cancer risk among those carrying two SNP309G
alleles. No association of SNP309 allele with colon, breast, or prostate cancer risk could be detected, but they noted an asso-
ciation of SNP309G with reduced lung cancer risk.
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sex and in multivariable analyses we adjusted for the match-
ing variables age and area of residence.
Statistical analyses were performed using the IBM SPSS sta-
tistics (version 19) software package and stata 13.0 for windows.
Results
Distribution of MDM2 SNP285 and SNP309
In this study 10,830 Norwegian individuals (7,081 cancer cases
and 3,749 healthy controls) were analyzed for MDM2 SNP285
and SNP309 status. Among the healthy controls, we observed
the minor allele frequencies (MAF) of SNP285 and SNP309 to
be 0.034 and 0.372 respectively. This is in accordance with previ-
ous ﬁndings in both Norwegians and Europeans in gen-
eral.23,24,28 The genotype distribution was found to be in Hardy-
Weinberg equilibrium for both SNPs (p> 0.126). No gender dif-
ferences regarding distribution of any of the haplotypes were
recorded (Chi-square; p5 0.723 and p5 0.530 for SNP309 and
SNP285 respectively), thus the association analyses (estimating
ORs) were performed both by treating healthy controls as one
homogenous group and after stratiﬁcation according to gender.
Similar to our previous analyses,16,19,24 we observed the
SNP285C variant exclusively in individuals harboring the
SNP309TG or GG genotype, conﬁrming SNP285C to reside
on a distinct SNP285C/309G haplotype.
Association Between MDM2 SNP309 and Cancer Risk
A comprehensive overview of the SNP309 distribution in the
four cancer types analyzed is given in Table 1. Using the
dominant model (SNP309GG1TG versus TT), we observed
no signiﬁcant association between SNP309 status and risk of
either breast, prostate or colon cancer. Recalculating the risk
estimates adjusting for age and gender did not change the
conclusions for either of the cancer types (Table 1).
Interestingly, we observed a negative association with
lung cancer risk for SNP309G carriers (dominant model,
SNP309TG1GG versus SNP309TT; Crude OR5 0.86; 95%
CI5 0.76–0.98; Table 1). Further stratiﬁcation suggested
that the negative association was present in individuals har-
boring the SNP309TG genotype (Crude OR5 0.84; 95%
CI5 0.74–0.96), but not for those harboring the SNP309GG
genotype (Crude OR5 0.94; 95% CI5 0.77–1.14; Support-
ing Information Table 1). Notably, SNP309 status was asso-
ciated with a reduced risk of lung cancer in women (age
and population adjusted OR5 0.77; 95% CI5 0.63–0.95),
but not in men (age and population adjusted OR5 0.91;
95% CI5 0.77–1.08).
Most studies addressing the effect of SNP309 status on
cancer risk have not included information on SNP285 status in
their analysis. In order to determine a potential confounding
Table 1. MDM2 SNP309 distribution and cancer risk
Genotype OR (95% CI) OR (95% CI)
SNP309 n (%)
SNP309 SNP309
Cases/controls TT TG GG GG1TG vs. TT Fisher exact GG vs. TG1TT Fisher exact
Controls 1464 (39.1) 1783 (47.6) 502 (13.4) 1.00 – 1.00 –
Women 740 (39.5) 878 (46.9) 254 (16.6) 1.00 – 1.00 –
Men 724 (38.6) 905 (48.2) 248 (13.2) 1.00 – 1.00 –
Controls1 1464 (41.9) 1615 (46.2) 416 (11.9) 1.00 – 1.00 –
Colon cancer 631 (41.2) 715 (46.7) 186 (12.1) 0.92 (0.81–1.03) 0.154 0.89 (0.75–1.07) 0.224
Women2 322 (41.3) 363 (46.6) 94 (12.1) 0.96 (0.81–1.15) 0.685 0.91 (0.70–1.19) 0.496
Men2 309 (41.0) 352 (46.8) 92 (12.2) 0.91 (0.77–1.10) 0.317 0.87 (0.67–1.13) 0.289
Colon cancer1 631 (44.1) 642 (44.9) 157 (11.0) 0.91 (0.81–1.03) 0.153 0.91 (0.75–1.11) 0.378
Lung cancer 567 (42.6) 581 (43.7) 183 (13.8) 0.86 (0.76–0.98) 0.025 1.03 (0.86–1.24) 0.744
Women2 228 (45.9) 203 (40.9) 66 (13.3) 0.77 (0.63–0.95) 0.014 0.91 (0.77–1.08) 0.278
Men2 339 (40.7) 378 (45.3) 117 (14.0) 0.91 (0.77–1.08) 0.278 1.03 (0.81–1.31) 0.790
Lung cancer1 567 (46.0) 520 (42.2) 145 (11.8) 0.85 (0.74–0.96) 0.012 0.99 (0.81–1.21) 0.918
Breast cancer 672 (39.1) 794 (46.2) 251 (14.6) 1.00 (0.89–1.12) 0.952 1.11 (0.94–1.30) 0.221
Women2,3 672 (39.1) 794 (46.2) 251 (14.6) 1.01 (0.88–1.16) 0.898 1.08 (0.98–1.31) 0.459
Breast cancer1 672 (41.6) 723 (44.8) 219 (13.6) 1.01 (0.90–1.14) 0.879 1.16 (0.89–1.39) 0.101
Prostate cancer 988 (39.5) 1169 (46.7) 344 (13.8) 0.98 (0.89–1.09) 0.731 1.03 (0.89–1.20) 0.678
Men2,4 988 (39.5) 1169 (46.7) 344 (13.8) 0.97 (0.86–1.10) 0.603 1.02 (0.86–1.22) 0.791
Prostate cancer1 988 (42.6) 1063 (45.8) 268 (11.6) 0.97 (0.87–1.08) 0.606 0.97 (0.82–1.14) 0.708
1Calculations without individuals carrying SNP285C.
2Age and population adjusted.
3Calculations against female controls only.
4Calculations against male controls only.
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effect of SNP285C, we reanalyzed the dataset after excluding
individuals carrying the minor SNP285C allele from both cases
and controls, but the estimated associations (ORs) remained
essentially unchanged (Table 1).
Since 94.5% of the lung cancer patients (from whom we
had data) were smokers, no formal assessment of a potential
interaction between smoking status, MDM2 SNP status and
lung cancer risk could be performed. Excluding non-smokers
from the analysis had little impact on the estimates (Support-
ing Information Table 1).
Association Between MDM2 SNP285 Status and Cancer
Risk
The proportion of SNP285CC carriers was 0.13% only; thus,
we assessed the potential impact of SNP285 on cancer risk
using the dominant model (genotypes CC1GC combined
versus GG). Overall assessment (testing for OR related to
SNP285 status with no stratiﬁcation for SNP309 status, and
with age, gender and population adjustments) showed no
clear associations between MDM2 SNP285C status and can-
cer risk for any of the cancer forms (Table 2/Fig. 1a).
Since the SNP285C allele resides on the SNP309G allele,
similar to what was done in our previous studies16,19; we
reﬁned the analyses by removing individuals harboring the
SNP309TT genotype, and stratiﬁed the data into the two sub-
groups of individuals harboring the SNP309TG - and GG
genotypes. Interestingly, this subgroup analysis showed a neg-
ative association of SNP285C with breast cancer among indi-
viduals carrying the SNP309GG genotype (OR5 0.71; 95%
CI 50.46–1.10; Table 3/Fig. 1b), but not among carriers of
the SNP309TG genotype (OR5 0.94; CI 0.71–1.26; Table 4/
Fig. 1c). Both these observations are in line with our previous
ﬁnding suggesting that SNP285C is negatively associated with
breast cancer risk among individuals homozygous for
SNP309GG but not among 309TG heterozygotes.16 Notably,
restricting the analysis to individuals from the same geo-
graphical regions of Norway as our previous study16 we
observed an even stronger negative association of SNP285C
with breast cancer risk in individuals harboring the
SNP309GG/285GC genotype (OR5 0.51; 95% CI5 0.31–
0.85; Supporting Information Table 2). Adjusting the esti-
mated OR for age, study population and gender gave similar
results (OR5 0.55; CI5 0.55; 95% CI5 0.33–0.93; Table 3/
Fig. 1b).
In the SNP309 stratiﬁed analysis, no effect of SNP285C
was observed on prostate cancer risk (Tables 3 and 4, Figs.
1b and 1c), conﬁrming our previous ﬁndings from a smaller
study.19 Among individuals harboring the SNP309TG geno-
type, we found that SNP285C was positively associated with
lung cancer risk in women (age and population adjusted
OR5 1.64; 95% CI5 1.01–2.66) but not in men (age and
population adjusted OR5 0.86; 95% CI5 0.56–1.32) (Table
4). Regarding cancer of the colon, we observed no clear effect
of SNP285 status among carriers of either SNP309TG or the
SNP309GG genotype among either males or females (Tables
3 and 4); nor did we observe any differences when tumors of
the right and the left side of the colon were analyzed for sep-
arately (Supporting Information Table 3).
Discussion
While SNP309G was initially found to accelerate tumor for-
mation in a hormone dependent manner and to be associated
Table 2. Effect of MDM2 SNP285 on breast, colon, lung, and prostate cancer
Genotype OR (95% CI)
SNP285 n (%)
SNP285
Cases/controls GG GC CC CC1GC vs. GG Fisher exact
Controls 3495 (93.2) 254 (6.8) 0 (0.0) 1.00 –
Women 1750 (93.5) 122 (6.5) 0 (0.0) 1.00 –
Men 1745 (93.0) 132 (7.0) 0 (0.0) 1.00 –
Colon cancer 1430 (93.3) 99 (6.5) 3 (0.2) 0.98 (0.77–1.25) 0.904
Women1 720 (92.4) 57 (7.3) 2 (0.3) 1.15 (0.82–1.61) 0.412
Men1 710 (94.3) 42 (5.6) 1 (0.1) 0.77 (0.54–1.12) 0.166
Lung cancer 1232 (92.6) 98 (7.4) 1 (0.1) 1.11 (0.87–1.41) 0.415
Women1 457 (92.0) 39 (7.9) 1 (0.2) 1.21 (0.83–1.77) 0.326
Men1 775 (93.0) 59 (7.1) 0 (0.0) 1.03 (0.74–1.42) 0.880
Breast cancer 1614 (94.0) 100 (5.8) 3 (0.2) 0.88 (0.69–1.11) 0.289
Women1,2 1614 (94.0) 100 (5.8) 3 (0.2) 0.89 (0.67–1.17) 0.395
Prostate cancer 2319 (92.7) 175 (7.0) 7 (0.3) 1.08 (0.89–1.32) 0.448
Men1,3 2319 (92.7) 175 (7.0) 7 (0.3) 1.01 (0.80–1.28) 0.931
1Age and population adjusted.
2Calculations against female controls only.
3Calculations against male controls only.
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with an increased risk of several malignancies,11,12,29 subse-
quent case control studies examining the OR for different
cancer forms across different ethnic populations have yielded
conﬂicting results.13–15,30–34 Taken together, much evidence
points to a difference related to ethnicity, in as much as most
individual studies have reported a positive association
between the SNP309G genotype and tumor risk in Asians
but not in Europeans.13,14 Notably, most individual reports
have enrolled a limited number of participants in their stud-
ies. In addition, the case control design of many studies may
imply potential biased comparisons between patient and con-
trol groups, and a publication bias in favor of studies report-
ing positive results cannot be excluded.
There are several strengths of our study. First, the number
of participants is high compared to other studies that have
addressed MDM2 SNPs and cancer risk. Second, this is a
population-based study, where incident cancer cases and con-
trols without cancer are drawn from the same underlying
population. Third, the controls were matched to the cases
with respect to sex, age and county of residence.
In this study, we found no association between MDM2
SNP309 genotypes and the risk of either colon-, breast- or
prostate cancer. While cancer of the left and the right side of
the colon may differ according to age at diagnosis and genetic
disposition,35 subgroup analyses indicated no association
between either of the two MDM2 SNPs and the risk for either
cancer of the left or the right side of the colon. Our observa-
tions regarding breast and colon cancer risk with respect to
SNP309T/G status are in line with previous reports,16,28,36 sug-
gesting that the SNP309G allele may increase the risk in Asian
populations37 but not in Caucasians14,15 Further, our ﬁnding
that SNP309 status was not associated with risk for prostate
cancer is in line with our previous ﬁnding in a smaller Norwe-
gian study where some prostate cancer cases, but only 1.9% the
controls, overlapped with the cases of our study.19 The ﬁnding,
however, differs from the results by Liu et al., who reported
that the SNP309G allele may be negatively associated with
prostate cancer risk in Caucasians.31 Notably, the number of
individuals analyzed in our study (2,501 prostate cancer
patients and 3,749 healthy controls) are substantially higher
than the number of individuals enrolled in the study by Liu
et al (872 prostate cancer patients and 1,005 healthy controls),
raising the possibility that the ﬁndings by Liu et al31 may have
occurred by chance.
Our ﬁnding that the SNP309G allele was associated with a
reduced risk for lung cancer in individuals harboring the
SNP309TG genotype differs from the ﬁndings of another
Norwegian study which reported that carriers of the
SNP309GG genotype may be at increased risk of lung cancer.38
However, that study included a limited number of individuals
(341 cases and 412 controls). In contrast, our present ﬁndings
are in line with the observations of Li et al. who conducted a
case–control study of 1,026 cases and 1,145 controls.39 Notably,
they reported a reduced risk among women, but not among
men, indicating a possible gender difference with respect to
SNP309 status and lung cancer risk. Interestingly, we observed
that the SNP309G-allele was negatively associated with lung
cancer risk among individuals carrying the SNP309TG but not
Figure 1. Impact of SNP285 on cancer risk. Forest plots showing the
effect of SNP285 on colon, lung, breast and prostatic cancer, as
compared to healthy controls, among the total study population (a),
among individuals harboring the SNP309GG genotype (b) and the
SNP309TG genotype (c). ORs were calculated as crude ORs for each
cancer type. In addition, ORs were calculated using gender matched
controls only, with adjustments for age and population (*).
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the GG genotype. Similar genetic differences have been
observed for other genes, where heterozygous and homozygous
carriers may be susceptible to different diseases.40
In contrast to SNP309, only a few studies have explored
the effect of the recently identiﬁed MDM2 polymorphism;
SNP285. The SNP285C variant resides on the SNP309G allele
and creates a distinct SNP285C/309G haplotype.16,17 This
haplotype is widespread across Caucasian populations, but
appear to be absent among ethnic Asians and Africans.24
Previously, we and others have reported that the SNP285C
variant may be associated with reduced risk for breast,16,20
ovarian16 and endometrial19 cancer, and others reported a
reduced age at cancer diagnosis related to the SNP285G allele
among individuals with the Li-Fraumeni syndrome.41 In con-
trast, previous reports have indicated SNP285C not to be
associated with the risk of either lung21 or prostate cancer.19
Table 3. Effect of MDM2 SNP285C among SNP309GG
Genotype OR (95% CI)
SNP285 n (%)
SNP285
Cases/controls GG GC CC CC1GC vs. GG Fisher exact
Controls 416 (82.9) 86 (17.1) 0 (0.0) 1.00 –
Women 208 (81.9) 46 (18.1) 0 (0.0) 1.00 –
Men 208 (83.9) 40 (16.1) 0 (0.0) 1.00 –
Colon cancer 157 (84.4) 26 (14.0) 3 (1.6) 0.89 (0.57–1.41) 0.730
Women1 76 (80.9) 16 (17.0) 2 (2.1) 0.85 (0.44–1.67) 0.541
Men1 81 (88.0) 10 (10.9) 1 (1.1) 0.59 (0.27–1.29) 0.186
Lung cancer 145 (79.2) 37 (20.2) 1 (0.6) 1.27 (0.83–1.94) 0.313
Women1 53 (80.3) 12 (18.2) 1 (1.5) 0.80 (0.37–1.73) 0.571
Men1 92 (78.6) 25 (21.4) 0 (0.0) 1.49 (0.83–2.68) 0.178
Breast cancer 219 (87.3) 29 (11.6) 3 (1.2) 0.71 (0.46–1.10) 0.137
Women1,2 219 (87.3) 29 (11.6) 3 (1.2) 0.55 (0.33–0.93) 0.027
Prostate cancer 268 (77.9) 69 (20.1) 7 (2.0) 1.37 (0.97–1.94) 0.076
Men1,3 268 (77.9) 69 (20.1) 7 (2.0) 1.35 (0.86–2.11) 0.187
1Age and population adjusted.
2Calculations against female controls only.
3Calculations against male controls only.
Table 4. Effect of MDM2 SNP285C among SNP309TG
Genotype OR (95% CI)
SNP285 n (%)
SNP285
Cases/controls GG GC CC GC vs. GG Fisher exact
Controls 1615 (90.6) 168 (9.4) – 1.00 –
Women 802 (91.3) 76 (8.7) – 1.00 –
Men 813 (89.8) 92 (10.2) – 1.00 –
Colon cancer 642 (89.8) 73 (10.2) – 1.09 (0.82–1.46) 0.549
Women1 322 (88.7) 41 (11.3) – 1.39 (0.91–2.12) 0.131
Men1 320 (90.9) 32 (9.1) – 0.86 (0.56–1.33) 0.495
Lung cancer 520 (89.5) 61 (10.5) – 1.13 (0.83–1.54) 0.467
Women1 176 (86.7) 27 (13.3) – 1.64 (1.01–2.66) 0.045
Men1 344 (91.0) 34 (9.0) – 0.86 (0.56–1.32) 0.490
Breast cancer 723 (91.1) 71 (8.9) – 0.94 (0.71–1.26) 0.769
Women1,2 723 (91.1) 71 (8.9) – 1.02 (0.72–1.44) 0.925
Prostate cancer 1063 (90.9) 106 (9.1) – 0.96 (0.74–1.24) 0.795
Men1,3 1063 (90.9) 106 (9.1) – 0.83 (0.62–1.24) 0.232
1Age and population adjusted.
2Calculations against female controls only.
3Calculations against male controls only.
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We found the SNP285C to be associated with reduced
breast cancer risk among individuals harboring the
SNP309GG genotype, but found no association among indi-
viduals harboring the SNP309TG genotype. While these ﬁnd-
ings may be surprising, both observations are in accordance
with our previous ﬁndings in large independent cohorts of
Norwegian as well as Dutch breast cancer patients and con-
trols.16 Notably, restricting the analysis to individuals from
the same regions as our previous study (excluding participants
from the Northern Norway), the association between
SNP285C and a reduced risk for breast cancer became highly
signiﬁcant. Recently, we showed the SNP285C variant to be
rare among individuals of Finnish and Saami ethnicity;24 thus
the altered OR may be explained by an admixture of Finnish
and Saami genes in the population of Northern Norway.
Further, our ﬁndings of no association between SNP285
status and risk of prostate cancer is in accordance with our
previous ﬁndings in a smaller subset of prostate cancer
patients.19 Although approximately 25% of the prostate can-
cer patients have been reported in a previous study, the risk
assessments in this study were carried out using a different
group of healthy controls.
Also, with respect to lung cancer our overall data are in
line with a smaller study assessing the impact of SNP285 and
SNP309 in American cancer patients.21 Regarding colon can-
cer, to the best of our knowledge no previous study has
addressed OR for this malignancy related to SNP285C status.
In silico predictions have shown that SNP285 is located
within a half-ERE sequence overlapping with a Sp1 binding
site in the MDM2 promoter,19 and in vitro experiments has
shown that Sp1 and ESR1 cooperatively binds to such half-
sites.42 Based on this ﬁnding, we hypothesized the cancer risk
reducing effect of SNP285C to be gender speciﬁc. Stratifying
our datasets for colon and lung cancer into subgroups of
females and males revealed no gender-dependent effect of
SNP285C for colon cancer and a slight increase in the risk of
lung cancer among females with SNP285C and the
SNP309TG genotype. Although it has been proposed that
female sex hormones are associated with lung cancer
risk,43–45 our ﬁnding may have occurred by chance, and
needs to be conﬁrmed in independent studies.
Taken together, our results obtained from a large Norwe-
gian cohort indicate little effect of SNP309 genotypes on the
OR for the four most frequent cancer forms in the Norwe-
gian population in respect to any gender. Importantly;
excluding individuals carrying the SNP285C/309G haplotype
from the analysis had little impact on outcome; thus, our
data indicate the presence of the SNP285C/309G haplotype
among Caucasians, may not alone explain the potential dis-
crepancy with respect to cancer risk between Caucasians and
Asians as indicated in the literature.
We found no effect of SNP285C status on OR for either
cancer of the lung or colon in either gender. Further, we
conﬁrmed our previous ﬁnding that SNP285C/G status may
not inﬂuence the risk of prostate cancer.19 However, we did
conﬁrm our previous ﬁnding of a reduced breast cancer risk
related to the C-allele among women carrying the
SNP309GG genotype.16 Importantly, the data presented
here indicate that the effect of SNP285C is likely to be tis-
sue speciﬁc rather than gender speciﬁc. Therefore further
studies evaluating the effect of SNP285C on additional
cancer types are warranted.
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